Europe's first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder - Marketscreener.com
Submitted by Anonymous (not verified) on Tue, 05/03/2022 - 05:01
